<!DOCTYPE html>
<html lang="" xml:lang="">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>2 AMR situation in Italy | 97039 - GLOBAL HEALTH, ANTIMICROBIAL DRUGS AND VACCINES</title>
  <meta name="description" content="2 AMR situation in Italy | 97039 - GLOBAL HEALTH, ANTIMICROBIAL DRUGS AND VACCINES" />
  <meta name="generator" content="bookdown 0.24 and GitBook 2.6.7" />

  <meta property="og:title" content="2 AMR situation in Italy | 97039 - GLOBAL HEALTH, ANTIMICROBIAL DRUGS AND VACCINES" />
  <meta property="og:type" content="book" />
  
  
  
  

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="2 AMR situation in Italy | 97039 - GLOBAL HEALTH, ANTIMICROBIAL DRUGS AND VACCINES" />
  
  
  

<meta name="author" content="Russell E. Lewis, Associate Professor, Infectious Diseases, University of Bologna" />


<meta name="date" content="2022-11-26" />

  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  
  
<link rel="prev" href="what-are-the-drivers-of-antimicrobial-resistance.html"/>
<link rel="next" href="the-future-of-amr.html"/>
<script src="libs/header-attrs-2.11/header-attrs.js"></script>
<script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/fuse.js@6.4.6/dist/fuse.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />








<link href="libs/anchor-sections-1.0.1/anchor-sections.css" rel="stylesheet" />
<script src="libs/anchor-sections-1.0.1/anchor-sections.js"></script>



<style type="text/css">
/* Used with Pandoc 2.11+ new --citeproc when CSL is used */
div.csl-bib-body { }
div.csl-entry {
  clear: both;
}
.hanging div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}
</style>

</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li class="chapter" data-level="1" data-path="what-are-the-drivers-of-antimicrobial-resistance.html"><a href="what-are-the-drivers-of-antimicrobial-resistance.html"><i class="fa fa-check"></i><b>1</b> What are the drivers of antimicrobial resistance?</a>
<ul>
<li class="chapter" data-level="1.1" data-path="what-are-the-drivers-of-antimicrobial-resistance.html"><a href="what-are-the-drivers-of-antimicrobial-resistance.html#how-can-antimicrobials-be-used-to-preserve-their-effectiveness-and-delay-resistance-in-humans"><i class="fa fa-check"></i><b>1.1</b> How can antimicrobials be used to preserve their effectiveness and delay resistance in humans?</a></li>
</ul></li>
<li class="chapter" data-level="2" data-path="amr-situation-in-italy.html"><a href="amr-situation-in-italy.html"><i class="fa fa-check"></i><b>2</b> AMR situation in Italy</a></li>
<li class="chapter" data-level="3" data-path="the-future-of-amr.html"><a href="the-future-of-amr.html"><i class="fa fa-check"></i><b>3</b> The future of AMR</a></li>
<li class="chapter" data-level="4" data-path="one-health-perspective-of-amr.html"><a href="one-health-perspective-of-amr.html"><i class="fa fa-check"></i><b>4</b> One-Health Perspective of AMR</a>
<ul>
<li class="chapter" data-level="4.1" data-path="one-health-perspective-of-amr.html"><a href="one-health-perspective-of-amr.html#antibiotic-use-in-food-production"><i class="fa fa-check"></i><b>4.1</b> Antibiotic use in food production</a></li>
<li class="chapter" data-level="4.2" data-path="one-health-perspective-of-amr.html"><a href="one-health-perspective-of-amr.html#impacts-animal-antibiotic-use-on-human-amr"><i class="fa fa-check"></i><b>4.2</b> Impacts Animal antibiotic use on Human AMR</a>
<ul>
<li class="chapter" data-level="4.2.1" data-path="one-health-perspective-of-amr.html"><a href="one-health-perspective-of-amr.html#case-study-cephalosporins"><i class="fa fa-check"></i><b>4.2.1</b> Case study-cephalosporins</a></li>
<li class="chapter" data-level="4.2.2" data-path="one-health-perspective-of-amr.html"><a href="one-health-perspective-of-amr.html#case-study--colistin"><i class="fa fa-check"></i><b>4.2.2</b> Case study- colistin</a></li>
</ul></li>
<li class="chapter" data-level="4.3" data-path="one-health-perspective-of-amr.html"><a href="one-health-perspective-of-amr.html#environmental-concerns"><i class="fa fa-check"></i><b>4.3</b> Environmental concerns</a></li>
</ul></li>
<li class="chapter" data-level="5" data-path="amr-in-low-middle-income-countries-lmics.html"><a href="amr-in-low-middle-income-countries-lmics.html"><i class="fa fa-check"></i><b>5</b> AMR in Low-Middle Income Countries (LMICs)</a></li>
<li class="chapter" data-level="6" data-path="cross-boarder-spread-of-amr.html"><a href="cross-boarder-spread-of-amr.html"><i class="fa fa-check"></i><b>6</b> Cross-boarder spread of AMR</a></li>
<li class="chapter" data-level="7" data-path="summary.html"><a href="summary.html"><i class="fa fa-check"></i><b>7</b> Summary</a></li>
<li class="chapter" data-level="" data-path="references.html"><a href="references.html"><i class="fa fa-check"></i>References</a></li>
</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">97039 - GLOBAL HEALTH, ANTIMICROBIAL DRUGS AND VACCINES</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="amr-situation-in-italy" class="section level1" number="2">
<h1><span class="header-section-number">2</span> AMR situation in Italy</h1>
<p>Southern Europe, including Italy, has among the highest rates of resistance for pathogens included on the WHO Priority Pathogen list. For example, surveillance data from the European Centres for Disease Control (ECDC) have reported a dramatic increase in multidrug-resistance (MDR) in Italy since 2009, with now more than one-third of <em>Klebsiella pneumoniae</em> resistant to previously-considered last-line antibiotics such as carbapenems (Fig 1.4). The link to interactive ECDC resistance atlas can be found <a href="https://atlas.ecdc.europa.eu/public/index.aspx?Dataset=27&amp;HealthTopic=4">here</a>. Similarly, the Italian <a href="https://www.epicentro.iss.it/antibiotico-resistenza/epidemiologia-italia">Micronet Resistance Surveillance</a>) program has reported:</p>
<ul>
<li>26.4% of <em>Escherichia coli</em> are resistant to 3rd generation cephalosporins</li>
<li>29.5% of <em>Klebsiella pneumoniae</em> are resistant to carbapenems (including 33.1% resistant to multiple drug classes)</li>
<li>15.9% of <em>Pseudomonas aeruginosa</em> are resistant to carbapenemase</li>
<li>80.8% of <em>Acinetobacter</em> spp. are resistant to carbapenems with 78.8% of species resistant to multiple drug classes</li>
<li>For the Gram-positive organism <em>Staphylococcus aureus</em>, the percentage of methicillin-resistant isolates (MRSA) remained stable, around 34%, while a worrying trend continues to increase in the percentage of <em>Enterococcus faecium isolates</em> resistant to vancomycin, which in 2020 was equal at 23.6%</li>
<li>For <em>Streptococcus pneumoniae</em> there was a slight increase in both the percentage of isolates resistant to penicillin (13.6%) and those resistant to erythromycin (24.5%).</li>
<li>Overall, higher antimicrobial resistance rates (around 40%) are observed in ICUs versus general medical wards for both carbapenem-resistant <em>K. pneumoniae</em> and methicillin-resistant <em>S. aureus</em>.</li>
</ul>
<center>
<figure>
<p><img src="images/Italia_CRE.png" width="500" /></p>
<figcaption>
<p>Figure 1.4. Regional differences in carbapenem-resistant Enterobacterales (CRE) bloodstream infection- 2020 incidence per 100,000 residents in Italy. Source Micronet Resistance Surveillance Program</p>
</figcaption>
</figure>
</center>
<p>In 2017, a <a href="https://www.ecdc.europa.eu/en/publications-data/ecdc-country-visit-italy-discuss-antimicrobial-resistance-issues">report</a> by the the ECDC noted that the AMR situation in Italian hospitals and regions poses a major public health threat to the country. The levels of carbapenem-resistant Enterobacteriaceae (Enterobacterales) (CRE) and <em>Acinetobacter baumannii</em> have now reached hyper-endemic levels in many hospitals. Together with increasing methicillin-resistance among the Gram-positive species <em>Staphylococcus aureus</em> (MRSA), these resistance trends has led to Italyâ€™s ranking as one of the Member States with one of the highest level of antibiotic resistance in Europe. Factors noted by the ECDC that contributed negatively to the poor control of antibiotic resistance in Italy include:</p>
<ul>
<li>Little sense of urgency about the current AMR situation from most stakeholders and a tendency by many stakeholders to avoid taking charge of the problem</li>
<li>Lack of institutional support at national, regional and local level</li>
<li>Lack of professional leadership at each level</li>
<li>Lack of accountability at each level</li>
<li>Lack of coordination of the activities between and within levels.</li>
</ul>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="what-are-the-drivers-of-antimicrobial-resistance.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="the-future-of-amr.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"linkedin": false,
"weibo": false,
"instapaper": false,
"vk": false,
"whatsapp": false,
"all": ["facebook", "twitter", "linkedin", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": null,
"text": null
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": null,
"search": false,
"toc": {
"collapse": "subsection"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    var src = "true";
    if (src === "" || src === "true") src = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-MML-AM_CHTML";
    if (location.protocol !== "file:")
      if (/^https?:/.test(src))
        src = src.replace(/^https?:/, '');
    script.src = src;
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
